Annexin A2GENANXVANCT06880107
Genetic Variants of Annexin A2 and Cryptogenic Stroke
A study testing blood withdrawal in people with Annexin A2 and Stroke, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Annexin A2, Stroke, Genetic Variants of Host
- What is being tested?
- blood withdrawal
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 240 participants
- Where
- 1 siteFrance
- Study dates
- 8 Apr 2025to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients
- Age from 18 years old
Who cannot join
- Transient ischemic attack
- Pregnancy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHRU Amiens
Amiens, 80054
Valéry Salle, MD, 33+3 22 66 82 30, salle.valery@chu-amiens.fr
Olivier GODEFROY, Pr
About this study
Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Genetic variants of tPA and PAI-1 genes have been suggested to be the risk factors for stroke.
ANXA2 plays a pivotal role in plasmin generation and fibrinolysis. Several studies showed the role of ANXA2 and S100A10 subunits in regulation of fibrinolysis in vivo. Recently, the efficacy of recombinant ANXA2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. Some single nucleotide polymorphisms in ANXA2 gene could be associated with increased risk of stroke in sickle cell disease.
Therefore, these data invite us to test hypothesis that genetic variants of ANXA2 gene could be associated with ischemic stroke.
- Conditions
- Annexin A2, Stroke, Genetic Variants of Host, Fibrinolysis
- Being tested
- blood withdrawal
- Keywords
- annexin A2, stroke, genetic variants, fibrinolysis
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood withdrawalBiological
blood withdrawal
| Study group | Role | What they receive |
|---|---|---|
| cryptogenic stroke | Experimental | cryptogenic stroke Receives: Biological: blood withdrawal |
| ischemic stroke | Experimental | ischemic stroke Receives: Biological: blood withdrawal |
| control subjects | Active comparator | control subjects Receives: Biological: blood withdrawal |
What is being measured
The primary outcome is the main question the study is designed to answer.
genetic variants of ANXA2
Measured: day 1
genetic variants of S100A10
Measured: day 1
Secondary outcomes (4)
blood ANXA2 concentration
Measured: day 1
blood S100A10 concentration
Measured: day 1
concentration of Autoantibodies directed against ANXA2
Measured: day 1
concentration of S100A10 directed against ANXA2
Measured: day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2025
- Study start8 Apr 2025
- Primary completionApr 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Annexin A2Studies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire, AmiensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06880107
- Sponsor's protocol ID
- PI2023_843_0150
- Acronym
- GENANXVA
- Status last verified
- Jan 2026
- First submitted
- 11 Mar 2025
- Last updated
- 16 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genetic Variants of Annexin A2 and Cryptogenic Stroke
- ClinicalTrials.gov ID
- NCT06880107
- Acronym / sponsor ID
- GENANXVA / PI2023_843_0150
- Conditions
- Annexin A2, Stroke, Genetic Variants of Host, Fibrinolysis
- Keywords
- annexin A2, stroke, genetic variants, fibrinolysis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensUniversity, hospital or other
- Study start
- 8 Apr 2025 (actual)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 17 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Genetic variants of tPA and PAI-1 genes have been suggested to be the risk factors for stroke.
ANXA2 plays a pivotal role in plasmin generation and fibrinolysis. Several studies showed the role of ANXA2 and S100A10 subunits in regulation of fibrinolysis in vivo. Recently, the efficacy of recombinant ANXA2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. Some single nucleotide polymorphisms in ANXA2 gene could be associated with increased risk of stroke in sickle cell disease.
Therefore, these data invite us to test hypothesis that genetic variants of ANXA2 gene could be associated with ischemic stroke.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| cryptogenic stroke | Experimental | Biological: blood withdrawalcryptogenic stroke |
| ischemic stroke | Experimental | Biological: blood withdrawalischemic stroke |
| control subjects | Active comparator | Biological: blood withdrawalcontrol subjects |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients
- Age from 18 years old
Key exclusion criteria (2 listed)
- Transient ischemic attack
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood withdrawalblood withdrawal | Biological | control subjects, cryptogenic stroke, ischemic stroke |
Primary outcome
genetic variants of ANXA2
Time frame: day 1
genetic variants of S100A10
Time frame: day 1
4 secondary outcomes
blood ANXA2 concentration
Time frame: day 1
blood S100A10 concentration
Time frame: day 1
concentration of Autoantibodies directed against ANXA2
Time frame: day 1
concentration of S100A10 directed against ANXA2
Time frame: day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Annexin A2
RecruitingObservational study
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection
COVID-19
RecruitingObservational study
68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
Breast Neoplasms、Lung Neoplasms、Pancreatic Neoplasms
Not yet recruiting
Undiluted and Diluted Nutrition
Critical Illness, Gastro Intestinal Surgery
Recruiting
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
Antiphospholipid Syndrome
Not yet recruiting
Diluted and Undiluted Enteral Nutrition
Critical Illness, Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing blood withdrawal in people with Annexin A2 and Stroke, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Valéry SALLE, MD (33+3 22 66 82 30, salle.valery@chu-amiens.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
genetic variants of ANXA2 (time frame: day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.